Scholarlink

<p>The rising global prevalence of chronic metabolic conditions, including cardiovascular diseases, diabetes, obesity, and cancer, demands the development of novel, safe, and effective therapeutic interventions. This review critically evaluates the therapeutic potential of bioactive peptides (BAPs) and protein hydrolysates derived from <i>Spirulina platensis</i> (Arthrospira); a nutrient-dense cyanobacterium increasingly recognized as a functional food source. Synthesizing evidence from in vitro, in vivo, and preclinical studies, we highlight <i>Spirulina</i>-based BAPs as promising nutraceutical agents with diverse biological activities. We examine various extraction and hydrolysis methods used to isolate these peptides and assess their efficacy in modulating key metabolic pathways. Notably, <i>Spirulina</i> BAPs have demonstrated potent antihypertensive effects by inhibiting Angiotensin-Converting Enzyme (ACE), alongside antidiabetic mechanisms through suppression of Dipeptidyl Peptidase-IV (DPP-IV), α-amylase, and α-glucosidase, while enhancing glycogen synthase activity. Additionally, robust antioxidant activity has been observed across multiple assays, with accumulating evidence supporting their antiproliferative effects on various cancer cell lines. Emerging findings also suggest potential roles in ameliorating hyperlipidaemia, inflammation, and obesity. Together, these findings position <i>Spirulina</i>-derived peptides as multifunctional bioactives with significant implications for metabolic health. However, to facilitate clinical translation, future research must prioritize well-designed animal models and rigorously controlled human trials. Moreover, advancements in peptide delivery systems particularly nanoencapsulation and targeted release technologies will be essential to enhance their stability, bioavailability, and therapeutic efficacy. Integrating such strategies may pave the way for incorporating <i>Spirulina</i>-based BAPs into evidence-based approaches for chronic disease prevention and management.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bioactive peptides from Spirulina platensis as emerging therapeutics for noncommunicable diseases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月14日

查看全文
  • Ahmad Ali,
  • Aliza Fatima,
  • Sanaullah Iqbal,
  • Azmatullah Khan,
  • Eisha Tariq,
  • Muhammad Saleh Zafar Mirza,
  • Saad bin Junaid,
  • Shahzad Ahmad,
  • Muniba Khaliq

摘要

The rising global prevalence of chronic metabolic conditions, including cardiovascular diseases, diabetes, obesity, and cancer, demands the development of novel, safe, and effective therapeutic interventions. This review critically evaluates the therapeutic potential of bioactive peptides (BAPs) and protein hydrolysates derived from Spirulina platensis (Arthrospira); a nutrient-dense cyanobacterium increasingly recognized as a functional food source. Synthesizing evidence from in vitro, in vivo, and preclinical studies, we highlight Spirulina-based BAPs as promising nutraceutical agents with diverse biological activities. We examine various extraction and hydrolysis methods used to isolate these peptides and assess their efficacy in modulating key metabolic pathways. Notably, Spirulina BAPs have demonstrated potent antihypertensive effects by inhibiting Angiotensin-Converting Enzyme (ACE), alongside antidiabetic mechanisms through suppression of Dipeptidyl Peptidase-IV (DPP-IV), α-amylase, and α-glucosidase, while enhancing glycogen synthase activity. Additionally, robust antioxidant activity has been observed across multiple assays, with accumulating evidence supporting their antiproliferative effects on various cancer cell lines. Emerging findings also suggest potential roles in ameliorating hyperlipidaemia, inflammation, and obesity. Together, these findings position Spirulina-derived peptides as multifunctional bioactives with significant implications for metabolic health. However, to facilitate clinical translation, future research must prioritize well-designed animal models and rigorously controlled human trials. Moreover, advancements in peptide delivery systems particularly nanoencapsulation and targeted release technologies will be essential to enhance their stability, bioavailability, and therapeutic efficacy. Integrating such strategies may pave the way for incorporating Spirulina-based BAPs into evidence-based approaches for chronic disease prevention and management.

Graphical Abstract